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The murine monoclonal antibody 791T/36,
originally prepared against a cultured human
osteogenic sarcoma cell line, 791T (Embleton et al.,
1981) has been used for successful clinical
radioimaging of both primary tumours and their
metastases. Investigations have been completed
upon osteogenic sarcomas (Farrands et al., 1983)
and colorectal carcinomas (Farrands et al., 1982;
Armitage et al., 1983; Pimm et al., 1984). In studies
on colorectal cancer, autoradiography of tumours
resected from patients given 1311-labelled 791T/36
antibody has indicated that the antibody
predominantly localizes in stromal elements and
secretions within pseudoacini rather than showing a
clear cut binding to malignant cells (Armitage et
al., 1983). The present study was therefore initiated
in order to examine whether the localization of
antibody to colorectal carcinomas is driven by an
immune mechanism whereby the 791T/36
monoclonal antibody reacts with an antigen
expressed within the tumour.
The preparation and purification of 791T/36
monoclonal antibody and normal mouse IgG2b
and their labelling with radioiodine for clinical
imaging trials have been previously described
(Farrands et al., 1982). Tumour and normal tissue
were resected from patients injected 1 to 3 days
previously with 13II-labelled 791T/36 monoclonal
antibody (70 MBq, 200,ug antibody) -as part of a
diagnostic imaging trial, (Armitage et al., 1983).
One patient received a mixture of 1311-719T/36
antibody (15MBq) and 1231-normal mouse IgG2b
(25 MBq). Weighed samples of tumour and normal
tissues were counted for 131I and in one case, for
1231, using an LKB-Wallac Gamma Counter.
As shown in Table I, the tumour to normal tissue
ratios 131I per g were 3.3:1, 2.0:1 and 1.8:1 for
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Patients 1, 2 and 3 respectively. Ratios of 2.0:1 or
greater represent the level of uptake in tumours
which permits successful external radioimaging of
tumours using a blood pool subtraction technique,
provided that the tumour image is not obscured by
that of 131I accumulating in the bladder (Armitage
et al., 1983; Pimm et al., 1984). With Patient no. 1
who received 1311-labelled 791T/36 antibody
admixed with 123I-labelled mouse IgG of the same
isotype (IgG2b), it was evident that there was no
localization of mouse IgG within the tumour
(tumour:normal tissue ratio for 1231 1.2:1) despite
the fact that there was more than 3-fold uptake of
'3'I into this specimen (tumour:normal tissue
uptake for 1311=3.3: 1) (Table I). This finding is
consistent with the view that 791T/36 antibody
localization within the tumour is mediated by an
immunological process.
Since autoradiographic studies of tumour from
patients infused with '311-labelled 791T/36 antibody
have shown that a major localization of antibody
was in stromal elements of the tumour (Armitage
et al., 1983), procedures were developed for the
further analysis of this material. Finely chopped
specimens were passed through a 60-mesh stainless
steel grid upon which fibrous material is retained
and compressed in this tissue press. This procedure
is based upon that described by Snary et al. (1976)
who developed a method for tissue disruption using
a mechanical press which retained fibrous material
and connective tissue elements on the grid. In each
case, the majority of radioactivity from tumour
tissue was recovered upon the grid while the bulk
of the disrupted tissue passed through the grid. The
mean recovery of radioactivity in fibrous material
on the grid was 87, 83 and 74% for tumour
specimens from Patients 1, 2 and 3 respectively
(Table I).
To permit further analysis of radioactive material
retained upon the grid, solubilization with non-
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Table I Localization of 1311-labelled 791T/36 monoclonal antibody in primary human colorectal
carcinomas
Clinical Details Patient I Patient 2 Patient 3
Tumour type: Rectal Caecum Sigmoid
adenocarcinoma adenocarcinoma adenocarcinoma
Duke's stage: B B C
Degree of differentiation: moderate well moderate
Tumour size (mm) 30 x 20 35 x 35 85 x 60
Patient infused with: 1311-791T/36 1311-791T/36 131I-791T/36
+ 1231-IgG2b
Period between antibody infusion
and tumour resection (days): 1 3 3
Distribution ofradioactivity
% of dose of 1311-791T/36 per g
of tumour tissue: 0.008 0.003 0.004
Tumour:normal tissue ratio: 3.3:1(1311) 2.0:1(1311) 1.8:1(1311)
1.2: 1(1231)
%Radioactivity (1311) Recovered
in Fibrous Material from
tumour tissue: 87 83 74
ionic detergent was attempted. With specimens
from Patients 2 and 3 (Table I), the fibrous residues
on the grid were extracted with detergent at a ratio
of -2ml detergent solution per g of original tissue.
This was achieved by repeated extraction with
20mMTris-HCl, 100mMNaCl, 1 mMEDTA, 0.5%
Nonidet P-40, pH8.0 (termed TNEN buffer),
homogenization using an Ultra Turrax homogeniser
(Janke & Kunkel, Ika-Werk) followed by
centrifugation at lOOOg for 20min and then re-
extraction of the pellets. This was continued for 3
or 4 cycles until the release of radioactivity into the
supernatants was minimal (i.e. <5% of the total
counts). The supernatants were combined and
centrifuged ay 78,000g for 30min and this final
supernatant was taken as the soluble extract of
fibrous residue.
A sample of soluble extract (2ml) from Patient
number 2 (Table I) was examined by gel filtration
on Sephacryl S-300 (Pharmacia, Uppsala, Sweden -
Column dimensions 90 x 1.5cm). The column was
equilibrated in, and eluted with, TNEN buffer and
calibrated for the elution of free antibody with 125I1
labelled 791T/36 antibody. In this case, 43% of the
1311-radioactivity was initially recoved in a soluble
form. As shown in Figure la, after gel filtration
chromatography, 78% of the 13'I-radioactivity in
the detergent extract was excluded from the column
(peak maximum in fraction 54) with the remaining
material (22% of the 1311-radioactivity) separating
as a peak of lower molecular weight (peak
maximum in fraction 75, Figure la). 125I-labelled
791T/36 antibody, when chromatographed alone,
separated as a single peak (peak maximum in
fraction 74, - Figure lb) co-incident with the
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Figure 1 Gel filtration of detergent extract (2ml) of
tumour fibrous material from patient 1 (Table I), upon
Sephacryl S-300. (a) fractions were counted for 1311
derived from injected 13II-791T/36 monoclonal
antibody; (b) the separation of 1251-791T/36 upon the
same column eluted under identical conditions.ANTIGEN DIRECTED TUMOUR LOCALIZATION OF ANTIBODY 811
material of lower molecular weight in the detergent
extract. One interpretation of this experiment is
that following detergent extraction of the fibrous
material, 1311-labelled 791T/36 antibody is released
in a soluble form with the majority complexed with
solubilized antigen.
In order to explore whether detergent extracts of
this fibrous material contained '311-labelled 791T/36
antibody complexed with antigen, the following
antigen identification procedure was developed:
Aliquots (5ml) of soluble extract of fibrous
material prepared from tumour tissue from Patients
2 and 3 (Table I) were admixed with 0.2ml of a
20% (v/v) suspension of Affi-Gel 10 (Biorad
Laboratories, Watford, Herts) to which affinity
purified goat antimouse IgG antibodies had been
linked at 5mg antibody ml-' of Affi-Gel 10 and
pre-equilibrated with TNEN buffer. Incubtation at
4°C with rolling was continued for 20h and the
immunoadsorbent gel washed 5 times, each with
10ml TNEN. Approximately 50% of the 131I
activity present in the initial soluble extracts was
bound to the immunoadsorbent gel at this stage
reflecting the binding of 791T/36 antibodies (free or
complexed with antigen) to the gel. The total Affi-
Gel 10 pellet with its bound materials was labelled
with 1251 by the addition of 0.5mCi 1251 Na
(Amersham International, Amersham) and 0.5ml
chloramine T(25jug) added dropwise. Incubation at
0°C was continued for 20min and the reaction
terminated by the addition of 50 ul
Na2S205(25jug). The gel was then washed 5 times
by centrifugaton, each wash being with
10mlTNEN. To the final pellet 0.2ml3MNaSCN
in TNEN was added to release bound 791T/36
antibody (free or complexed with antigen) under
which conditions immune complexes would also
dissociate. The total mixture was applied to a PD
10 column (Pharmacia, Uppsala, Sweden)
equilibrated with TNEN and eluted with this
buffer. The gel excluded fractions containing the
bulk of the radioactivity (and putative reassociated
immune complexes and free antibody) were
incubated with 100 lul of a 25% (v/v) suspension of
Sepharose-Protein A (Pharmacia, Uppsala, Sweden)
in TNEN. After incubation with shaking at 4°C for
60min, the Sepharose-Protein A was washed 5
times with 10ml of TNEN containing 0.5% sodium
deoxycholate, 2% BSA and 0.1% SDS, and then 5
times each with 10ml of a 1/10 dilution of TNEN
in water.
To the final pellet 0.2ml of reducing sample
buffer was added (Laemmli, 1970), the sample was
boiled for 3min and after centrifugation, the
supematant was electrophoresed on an SDS-12%
polyacrylamide gel at 50v. The gel was stained for
protein with Coomassie Blue, and after destaining
the gel was dried and autoradiographed for up to
21 days at -70°C with preflashed Fuji X-ray film
(Fuji Photo Co. Ltd., Tokyo, Japan) and an
intersifying screen (Cawo, FRG).
After applying these procedures the following
results were obtained. Three bands developed on
the X-ray film after exposure to the dried gel upon
which material isolated from the tumour from
Patient 2 (Table I) was electrophoresed (Figure 2a).
The apparent molecular weights of two of these
bands at 50Kd and 25Kd corresponded to those
for the heavy and light chains of the 791T/36
IgG2b antibody. The third band at 72,000 daltons
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Figure 2 (a) the SDS PAGE and autoradiographic
analysis of putative immune complexes of 791T/36
antibody and antigen labelled with 1251 and isolated
from resected colon carcinoma (Patient 2-Table I).
(b) the radioimmunoprecipitation of 791T/36 antibody
defined antigen from detergent solubilized, 1251-labelled
791T cells, using 791T/36 antibody and Sepharose
Protein A as the precipitating agent (Price et al., 1983).
The positions of the mol.w marker proteins are
indicated on the right (mol.wt values are x 10-3).
Mol. w markers were myosin (200kd), phosphorylase b
(92Kd), bovine serum albumin (67Kd), IgG heavy
chain (50Kd), ovalbumin (45Kd) and IgG light chain
(25Kd).812 M.R. PRICE et al.
corresponded to that of the 791T/36 defined
antigen isolated from 791T cells (as shown in
Figure 2b) (Price et al., 1983) as assessed using
conventional radioimmunoprecipitation tests, SDS-
PAGE and autoradiography. Equivalent results
were obtained following extraction of tumour from
Patient 3 and analysis of radioiodinated isolated
immune precipitates by SDS-PAGE and
autoradiography. Again the apparent molecular
weight of the 791T/36 defined antigen was 72,000.
The conclusions from these studies are that
following infusion of 791T/36 antibody into colo-
rectal carcinoma patients, the antibody localizes
within the tumour and the preferential accumulation
of antibody therein is due to immune recognition
of, and binding to its target rather than by a non-
specific interaction between antibody and tumour.
In addition, when antigen is recovered from the
resected tumour specimen, it is identical at least
with respect to apparent mol.w, to that originally
expressed upon the immunizing osteogenic sarcoma
cell line used to produce the 791T/36 antibody.
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